EQT agrees €9.6bn takeover of Qiagen
Wednesday, October 21, 2026 · first reported by Private Equity Wire and 2 others
EQT is in advanced talks to buy Qiagen in a deal that would value the molecular testing company at more than $10bn, Bloomberg reported, as relayed by Private Equity Wire. The Swedish manager is said to have made a binding offer above $50 per share. KKR has also put in a bid. Qiagen's board is expected to meet this week to weigh a transaction. Qiagen's US-listed shares rose as much as 9.2% on the report, putting its value near $10.2bn. Talks continue, and no deal is certain.
- Firm
- EQT
- Deal value
- $10.6B
- Asset class
- Private equity
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
3 sourcesMore on EQT
Everything on this firm →- CVC explores Verisure take-private one year after €13.7bn IPOPrivate Equity Wire
- Permira exits Octus in $3.5bn LSEG acquisitionPrivate Equity Wire
- IFM Investors snaps up majority stake in U.K.’s largest ports group from CPP Investments, OMERSIREI +3
- Vinci Compass acquires AustralRe to launch permanent capital platformPrivate Equity Wire +1
- Centerbridge and Mubadala near £1bn Canaccord Wealth dealPrivate Equity Wire
- Weil-Led US PE Firm To Buy Ashtead In £505M DealLaw360